Guidance for type 2 inflammatory biomarkers

Area of Science:

• Pulmonology and Immunology
• Respiratory Medicine

Background:

• Type 2 inflammation, mediated by cytokines (IL-4, IL-5, IL-13) from T cells and innate lymphoid cells, alters airway structure and function.
• Inflammatory biomarkers (blood eosinophils, fractional exhaled nitric oxide, IgE) are crucial for diagnosing and managing asthma and COPD.
• Diverse inflammatory phenotypes exist in asthma and COPD, necessitating biomarker assessment for accurate diagnosis and personalized treatment.

Purpose of the Study:

• To provide evidence-based guidelines for interpreting type 2 inflammation measurements.
• To promote the routine assessment of airway inflammation in clinical practice.
• To enhance the management of various airway and respiratory diseases.

Main Methods:

• Review and synthesis of existing evidence on type 2 inflammation biomarkers.
• Development of clinical practice guidelines for evaluating type 2 inflammation.
• Inclusion of diverse respiratory conditions beyond asthma and COPD.

Main Results:

• Established the role of biomarkers in improving diagnostic accuracy and treatment strategies.
• Highlighted the predictive value of inflammation assessment for exacerbations and lung function decline.
• Provided comprehensive guidance on interpreting a variety of clinical biomarkers.

Conclusions:

• Type 2 inflammation assessment is vital for optimizing the diagnosis and management of respiratory diseases.
• Biomarker-guided strategies improve treatment efficacy and patient outcomes.
• Guidelines facilitate the widespread adoption of inflammation assessment in clinical settings.